article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Pulmonary Resection for Lung Cancer Risk Calculator

Society of Thoracic Surgeons - Surgeon

Resource Pulmonary Resection for Lung Cancer Risk Calculator gmckinney Wed, 10/16/2024 - 07:59 The new pulmonary resection for lung cancer risk calculator is engineered using contemporary data from the STS General Thoracic Surgery Database.

Cancer 52
article thumbnail

Association of pulmonary hypertension with the outcome in patients undergoing edge-to-edge mitral valve repair

Heart BMJ

Objectives The association of pulmonary hypertension (PH) with the outcome after mitral transcatheter edge-to-edge repair (M-TEER) focusing on the new ESC/ERS guidelines definition for PH. to 2.07); p<0.001 and 2022: HR 2.09 (95% CI 1.54 to 2.07); p<0.001 and 2022: HR 2.09 (95% CI 1.54 to 2.83); p<0.001).

article thumbnail

Noninvasive evaluation of pulmonary hypertension using the second heart sound parameters collected by a mobile cardiac acoustic monitoring system

Frontiers in Cardiovascular Medicine

Background Pulmonary hypertension (PH) is linked to higher rates of morbidity and mortality worldwide. The estimated pulmonary artery systolic pressure (ePASP ≥ 35 mmHg) measured by echocardiography helps screen PH patients. Early diagnosis of PH is important for clinical treatment.

article thumbnail

Predictors of Outcomes in Mild Pulmonary Hypertension

American College of Cardiology

What is the impact on prognosis of the 2022 ESC/ERS pulmonary hypertension (PH) guidelines on the new redefined hemodynamic threshold for the diagnosis of precapillary PH?

article thumbnail

ECG Blog #396 — Why the Flat Line?

Ken Grauer, MD

KEY Point: Although true that patients with longstanding, severe pulmonary disease may manifest a QRST complex in standard lead I with marked overall reduction in QRST amplitude ( See ECG Blog #65 — regarding Schamroth’s Sign ) — you should never normally see a completely flat line in any of the standard limb leads.

Blog 178
article thumbnail

Patient Screening for Self?Expanding Percutaneous Pulmonary Valves Using Virtual Reality

Journal of the American Heart Association

BackgroundIn recent years, self‐expanding technology to treat pulmonary regurgitation in the native right ventricular outflow tract became Food and Drug Administration approved in the United States and is now routinely used. Journal of the American Heart Association, Ahead of Print.